How many patients were in the 4S trial?

The trial enrolled 4,444 patients with established coronary heart disease across 94 centers in Denmark, Finland, Iceland, Norway, and Sweden. Participants were followed for a median of 5.4 years.

What dose of simvastatin was used in 4S?

Patients started on 20 mg daily. The dose was increased to 40 mg at 6 or 12 weeks if total cholesterol remained above 5.2 mmol/L. About 37% of participants required the higher dose.

Did 4S include women?

Yes, but only 827 women (19% of participants). Coronary event reduction trended similarly to men, but the mortality analysis was underpowered for this subgroup. Later trials like HPS confirmed statin benefit in women.

Is simvastatin still prescribed today?

Yes. Simvastatin 20-40 mg remains widely available as a generic and is appropriate for patients needing moderate-intensity statin therapy. For patients requiring greater LDL reduction, atorvastatin or rosuvastatin are typically preferred.

What was the number needed to treat in 4S?

Approximately 30 patients needed treatment with simvastatin for 5.4 years to prevent one death. For major coronary events, the NNT was approximately 12.

Did 4S show increased cancer risk?

No. The trial found no significant increase in cancer or non-cardiovascular death in the simvastatin group, directly addressing concerns from earlier cholesterol-lowering studies.

How did 4S change cholesterol guidelines?

4S provided the mortality evidence that led NCEP ATP III, ACC/AHA, and ESC guidelines to mandate statin therapy as the default for patients with established atherosclerotic cardiovascular disease.

Can 4S results apply to patients without prior heart disease?

Not directly. 4S was a secondary prevention trial. Primary prevention evidence came from later studies like WOSCOPS, AFCAPS/TexCAPS, and JUPITER. The principle that LDL lowering reduces cardiovascular events does extend across the risk spectrum.

What are the main safety concerns with simvastatin?

Myopathy and rhabdomyolysis, especially at the 80 mg dose (which the FDA restricted in 2011) and with concurrent CYP3A4 inhibitors. The 20-40 mg range used in 4S carries a favorable safety profile.

Did patients over 70 benefit from simvastatin in 4S?

Patients over 70 were excluded. The PROSPER trial (2002) and HPS subgroup analyses later showed statin benefit in older adults, though with consideration for increased adverse effect risk.

What 4S Actually Changes in Clinical Practice

By HealthRX Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

What the 4S Trial Actually Changes in Clinical Practice

At a glance

| Detail | Value | |---|---| | Trial name | Scandinavian Simvastatin Survival Study (4S) | | N | 4,444 | | Intervention | Simvastatin 20 mg, titrated to 40 mg | | Comparator | Placebo | | Duration | Median 5.4 years | | Primary endpoint | All-cause mortality | | Key result | 30% relative risk reduction in all-cause mortality (p = 0.0003) |

Why 4S Still Matters 30 Years Later

Before 1994, physicians had reason to doubt whether lowering cholesterol would save lives. Earlier trials using non-statin therapies (clofibrate, cholestyramine) reduced cardiac events but showed no clear mortality benefit, and some raised concerns about increased non-cardiovascular deaths. The 4S trial settled the argument. A 30% reduction in all-cause mortality, driven by a 42% drop in coronary deaths, left little room for equipoise. That result did not simply add evidence to existing practice. It created a new standard of care.

Within two years of publication, prescribing of HMG-CoA reductase inhibitors in secondary prevention more than doubled across Europe and North America. The American Heart Association, the European Society of Cardiology, and the National Cholesterol Education Program all revised their guidelines to reflect what 4S demonstrated: for patients with known coronary heart disease and elevated cholesterol, statin therapy saves lives.

The Methodology Behind the Headline

Patient Selection Was Narrow by Design

The 4S investigators enrolled men and women aged 35 to 70 with a history of angina pectoris or prior myocardial infarction and baseline total cholesterol between 5.5 and 8.0 mmol/L (approximately 213-309 mg/dL). Patients with preplanned coronary surgery, secondary hyperlipidemia, or heart failure (NYHA class III-IV) were excluded.

This population was specific: Northern European, predominantly male (81%), with moderate-to-severe hypercholesterolemia and established coronary disease. The narrow enrollment criteria strengthened internal validity but limited direct extrapolation. Clinicians treating patients with lower baseline cholesterol, diabetes as a primary indication, or heart failure needed subsequent trials (CARE, LIPID, HPS) to confirm benefit in those populations.

Dose Titration Protocol

Participants started on simvastatin 20 mg daily. At 6 and 12 weeks, investigators titrated to 40 mg if total cholesterol remained above 5.2 mmol/L. Roughly 37% of participants required the higher dose. This titration-to-target approach contrasts with the modern "fire-and-forget" high-intensity statin strategy endorsed by the 2018 AHA/ACC cholesterol guidelines. The difference matters: 4S targeted a cholesterol number, while current practice prescribes a statin intensity regardless of baseline lipid levels.

Run-In and Blinding

An 8-week single-blind placebo run-in period preceded randomization, which eliminated poor compliers early. Compliance in the active arm exceeded 80% at trial end. The double-blind phase used matched placebo tablets, and investigators were blinded to individual lipid values during the trial.

Results: Beyond the Top-Line Number

Primary Endpoint

The primary analysis recorded 256 deaths in the placebo group versus 182 in the simvastatin group, a relative risk of 0.70 (95% CI 0.58-0.85, p = 0.0003). The absolute risk reduction was 3.3 percentage points over 5.4 years, yielding a number needed to treat (NNT) of approximately 30 to prevent one death.

Breakdown of Mortality

| Outcome | Simvastatin | Placebo | Relative Risk Reduction | |---|---|---|---| | All-cause mortality | 8.2% | 11.5% | 30% | | Coronary death | 5.0% | 8.5% | 42% | | Non-cardiovascular death | 2.1% | 1.9% | No significant difference |

The lack of excess non-cardiovascular death directly addressed a concern that had haunted cholesterol-lowering research for a decade. Prior meta-analyses had flagged possible increases in cancer, suicide, and violent death with lipid reduction. 4S found no such signal across 5.4 years of follow-up.

Secondary Endpoints

Major coronary events dropped by 34%. Revascularization procedures (CABG and PTCA combined) fell by 37%. Hospital days for cardiovascular causes decreased significantly, an early signal that statins could reduce healthcare costs in secondary prevention. These secondary results were later confirmed in economic analyses published using 4S data.

Subgroup Findings Worth Noting

Women comprised only 19% of the cohort (827 participants). The point estimate for coronary event reduction in women was similar to men, but the confidence interval was wide and the mortality analysis was underpowered for this subgroup. This limitation persisted until the Heart Protection Study (HPS) enrolled over 5,000 women and confirmed benefit.

Participants aged 60-70 derived at least as much benefit as younger patients. Diabetic subgroups (483 patients) showed a 55% reduction in major coronary events, a finding that generated hypothesis-forming data for later diabetes-specific statin trials.

What Changed in Clinical Practice

Guideline Revisions

The National Cholesterol Education Program (NCEP) ATP III guidelines, published in 2001 and updated in 2004, cited 4S as foundational evidence for recommending LDL targets <100 mg/dL in patients with established CHD. The 2013 ACC/AHA guidelines moved away from LDL targets entirely but retained high-intensity statin therapy as the default for secondary prevention, a position that traces directly back to the mortality proof 4S provided.

The European Society of Cardiology followed a parallel track. Their 2019 dyslipidemia guidelines pushed LDL targets below 55 mg/dL for very-high-risk patients, a threshold that would have been considered radical without the mortality evidence chain that 4S started.

Prescribing Patterns

Before 4S, many cardiologists reserved lipid-lowering drugs for patients with severe hypercholesterolemia who failed dietary modification. After 4S, the question flipped: the burden of proof shifted to justifying why a post-MI patient was not on a statin. This reversal showed up in prescription data. Statin use among post-MI patients in the United States climbed from under 10% in the early 1990s to over 80% by the early 2000s.

Simvastatin specifically became the most prescribed statin worldwide through the late 1990s and 2000s, partly because it had the mortality data. Its position eroded only after atorvastatin (ASCOT-LLA, TNT, CARDS) and rosuvastatin (JUPITER) accumulated their own evidence bases and offered more potent LDL reduction at comparable safety profiles.

The "Treat Earlier, Treat More Aggressively" Cascade

4S established that treating established CHD with statins saves lives. Subsequent trials extended the principle outward: WOSCOPS (1995) for primary prevention in high-risk men, AFCAPS/TexCAPS (1998) for moderate-risk patients, HPS (2002) for broader populations including diabetics and those with peripheral vascular disease. Each trial built on 4S, but none replaced it. The original finding, that mortality decreases with statin therapy in secondary prevention, remains the anchor.

Limitations the Authors Acknowledged

The 4S investigators were transparent about several constraints. The trial population was overwhelmingly white and Northern European. Only 19% were women. Patients with heart failure, very high or very low cholesterol, and those over 70 were excluded. Background therapy reflected early-1990s practice: beta-blockers were used in about 57% of patients, aspirin use was lower than current standards, and no participants were on modern dual antiplatelet therapy, high-intensity statins, or PCSK9 inhibitors.

The trial also did not assess outcomes below an LDL of approximately 120 mg/dL. Whether pushing LDL lower than what simvastatin achieved would yield additional mortality benefit required later work (TNT, IMPROVE-IT, FOURIER).

Safety Considerations

4S reported no significant increase in hepatotoxicity, myopathy, or cancer. Subsequent post-marketing surveillance and the simvastatin FDA label identified myopathy risk at the 80 mg dose, leading to a 2011 FDA safety communication restricting that dose. The 20-40 mg range used in 4S remains the recommended dosing window.

Rhabdomyolysis risk increases with drug interactions (particularly CYP3A4 inhibitors like clarithromycin, itraconazole, and certain HIV protease inhibitors). Clinicians prescribing simvastatin today must check for these interactions, a practical concern the original trial did not address because concomitant medications were more limited in the early 1990s.

What 4S Means for Patients Who Differ from the Trial Population

Patients with LDL below the 4S entry threshold still benefit from statins, as shown by CARE (1996) and HPS (2002). Patients over 75, excluded from 4S, received clearer guidance from the PROSPER trial (2002) and subgroup analyses within HPS, though the absolute benefit may be smaller and the risk of adverse effects (myalgia, cognitive complaints) modestly higher.

For patients with diabetes, the 4S diabetic subgroup was small but directionally strong. The Collaborative Atorvastatin Diabetes Study (CARDS, 2004) confirmed that diabetic patients without prior MI benefit from statin therapy, extending 4S into primary prevention for a high-risk metabolic population.

Patients of non-European descent were absent from 4S. Later trials (MEGA in Japan, HPS with broader recruitment) suggested similar relative risk reductions across ethnicities, though pharmacogenomic differences in statin metabolism (particularly SLCO1B1 variants affecting simvastatin specifically) mean that dose adjustments may be necessary for some populations.

The Bottom Line for Prescribers in 2026

4S answered a question that no longer needs asking: do statins reduce mortality in secondary prevention? They do. The clinical implications today are more granular. Simvastatin 20-40 mg remains a viable, inexpensive option for patients who need moderate-intensity statin therapy. For patients requiring more aggressive LDL lowering, atorvastatin 40-80 mg or rosuvastatin 20-40 mg offer greater potency. The choice is no longer whether to prescribe, but which agent and at what intensity.

The trial's lasting contribution is not the drug it tested. It is the principle it proved: that lowering LDL-C in patients with atherosclerotic disease reduces death, and that treating aggressively is better than treating cautiously. Every subsequent advance in lipid management, from ezetimibe combination therapy to PCSK9 inhibitors to bempedoic acid, stands on the foundation 4S laid.

Frequently asked questions

›

References

Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383-1389. PubMed
Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. J Am Coll Cardiol. 2019;73(24):e285-e350. PubMed
Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals. Lancet. 2002;360(9326):7-22. PubMed
Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. J Am Coll Cardiol. 2014;63(25 Pt B):2889-2934. PubMed
Simvastatin prescribing information. U.S. Food and Drug Administration. FDA Label